Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

Narjust Duma, Rafael Santana-Davila, Julian R Molina

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Lung cancer remains the leading cause of cancer deaths in the United States. In the past decade, significant advances have been made in the science of non–small cell lung cancer (NSCLC). Screening has been introduced with the goal of early detection. The National Lung Screening Trial found a lung cancer mortality benefit of 20% and a 6.7% decrease in all-cause mortality with the use of low-dose chest computed tomography in high-risk individuals. The treatment of lung cancer has also evolved with the introduction of several lines of tyrosine kinase inhibitors in patients with EGFR, ALK, ROS1, and NTRK mutations. Similarly, immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of NSCLC treatment. Furthermore, the results of new trials continue to help us understand the role of these novel agents and which patients are more likely to benefit; ICIs are now part of the first-line NSCLC treatment armamentarium as monotherapy, combined with chemotherapy, or after definite chemoradiotherapy in patients with stage III unresectable NSCLC. Expression of programmed cell death protein-ligand 1 in malignant cells has been studied as a potential biomarker for response to ICIs. However, important drawbacks exist that limit its discriminatory potential. Identification of accurate predictive biomarkers beyond programmed cell death protein-ligand 1 expression remains essential to select the most appropriate candidates for ICI therapy. Many questions remain unanswered regarding the proper sequence and combinations of these new agents; however, the field is moving rapidly, and the overall direction is optimistic.

Original languageEnglish (US)
Pages (from-to)1623-1640
Number of pages18
JournalMayo Clinic proceedings
Volume94
Issue number8
DOIs
StatePublished - Aug 1 2019

Fingerprint

Early Detection of Cancer
Non-Small Cell Lung Carcinoma
Programmed Cell Death 1 Receptor
Epidemiology
Lung Neoplasms
Biomarkers
Ligands
Mortality
Chemoradiotherapy
Proxy
Therapeutics
Protein-Tyrosine Kinases
Cause of Death
Thorax
Tomography
Drug Therapy
Lung
Mutation
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Non–Small Cell Lung Cancer : Epidemiology, Screening, Diagnosis, and Treatment. / Duma, Narjust; Santana-Davila, Rafael; Molina, Julian R.

In: Mayo Clinic proceedings, Vol. 94, No. 8, 01.08.2019, p. 1623-1640.

Research output: Contribution to journalReview article

Duma, Narjust ; Santana-Davila, Rafael ; Molina, Julian R. / Non–Small Cell Lung Cancer : Epidemiology, Screening, Diagnosis, and Treatment. In: Mayo Clinic proceedings. 2019 ; Vol. 94, No. 8. pp. 1623-1640.
@article{2b7fa89809ae42a5b5a52de6bee9b6db,
title = "Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment",
abstract = "Lung cancer remains the leading cause of cancer deaths in the United States. In the past decade, significant advances have been made in the science of non–small cell lung cancer (NSCLC). Screening has been introduced with the goal of early detection. The National Lung Screening Trial found a lung cancer mortality benefit of 20{\%} and a 6.7{\%} decrease in all-cause mortality with the use of low-dose chest computed tomography in high-risk individuals. The treatment of lung cancer has also evolved with the introduction of several lines of tyrosine kinase inhibitors in patients with EGFR, ALK, ROS1, and NTRK mutations. Similarly, immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of NSCLC treatment. Furthermore, the results of new trials continue to help us understand the role of these novel agents and which patients are more likely to benefit; ICIs are now part of the first-line NSCLC treatment armamentarium as monotherapy, combined with chemotherapy, or after definite chemoradiotherapy in patients with stage III unresectable NSCLC. Expression of programmed cell death protein-ligand 1 in malignant cells has been studied as a potential biomarker for response to ICIs. However, important drawbacks exist that limit its discriminatory potential. Identification of accurate predictive biomarkers beyond programmed cell death protein-ligand 1 expression remains essential to select the most appropriate candidates for ICI therapy. Many questions remain unanswered regarding the proper sequence and combinations of these new agents; however, the field is moving rapidly, and the overall direction is optimistic.",
author = "Narjust Duma and Rafael Santana-Davila and Molina, {Julian R}",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.mayocp.2019.01.013",
language = "English (US)",
volume = "94",
pages = "1623--1640",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "8",

}

TY - JOUR

T1 - Non–Small Cell Lung Cancer

T2 - Epidemiology, Screening, Diagnosis, and Treatment

AU - Duma, Narjust

AU - Santana-Davila, Rafael

AU - Molina, Julian R

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Lung cancer remains the leading cause of cancer deaths in the United States. In the past decade, significant advances have been made in the science of non–small cell lung cancer (NSCLC). Screening has been introduced with the goal of early detection. The National Lung Screening Trial found a lung cancer mortality benefit of 20% and a 6.7% decrease in all-cause mortality with the use of low-dose chest computed tomography in high-risk individuals. The treatment of lung cancer has also evolved with the introduction of several lines of tyrosine kinase inhibitors in patients with EGFR, ALK, ROS1, and NTRK mutations. Similarly, immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of NSCLC treatment. Furthermore, the results of new trials continue to help us understand the role of these novel agents and which patients are more likely to benefit; ICIs are now part of the first-line NSCLC treatment armamentarium as monotherapy, combined with chemotherapy, or after definite chemoradiotherapy in patients with stage III unresectable NSCLC. Expression of programmed cell death protein-ligand 1 in malignant cells has been studied as a potential biomarker for response to ICIs. However, important drawbacks exist that limit its discriminatory potential. Identification of accurate predictive biomarkers beyond programmed cell death protein-ligand 1 expression remains essential to select the most appropriate candidates for ICI therapy. Many questions remain unanswered regarding the proper sequence and combinations of these new agents; however, the field is moving rapidly, and the overall direction is optimistic.

AB - Lung cancer remains the leading cause of cancer deaths in the United States. In the past decade, significant advances have been made in the science of non–small cell lung cancer (NSCLC). Screening has been introduced with the goal of early detection. The National Lung Screening Trial found a lung cancer mortality benefit of 20% and a 6.7% decrease in all-cause mortality with the use of low-dose chest computed tomography in high-risk individuals. The treatment of lung cancer has also evolved with the introduction of several lines of tyrosine kinase inhibitors in patients with EGFR, ALK, ROS1, and NTRK mutations. Similarly, immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of NSCLC treatment. Furthermore, the results of new trials continue to help us understand the role of these novel agents and which patients are more likely to benefit; ICIs are now part of the first-line NSCLC treatment armamentarium as monotherapy, combined with chemotherapy, or after definite chemoradiotherapy in patients with stage III unresectable NSCLC. Expression of programmed cell death protein-ligand 1 in malignant cells has been studied as a potential biomarker for response to ICIs. However, important drawbacks exist that limit its discriminatory potential. Identification of accurate predictive biomarkers beyond programmed cell death protein-ligand 1 expression remains essential to select the most appropriate candidates for ICI therapy. Many questions remain unanswered regarding the proper sequence and combinations of these new agents; however, the field is moving rapidly, and the overall direction is optimistic.

UR - http://www.scopus.com/inward/record.url?scp=85069823964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069823964&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2019.01.013

DO - 10.1016/j.mayocp.2019.01.013

M3 - Review article

C2 - 31378236

AN - SCOPUS:85069823964

VL - 94

SP - 1623

EP - 1640

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 8

ER -